In our current study, the patients with adenocarcinoma harboring a single sensitizing uncommon mutation had a fine initial treatment response to first-line EGFR TKIs (disease control rate of 85%), PFS (median, 7.7 months), and OS (median, 18.4 months). The gene discussed is EGFR; the disease is adenocarcinoma.